Answers are grounded in this paper and cite their sources.
This review evaluates bexmarilimab's role in enhancing cancer therapy by targeting myeloid-driven immunosuppression, suggesting improvements in patient selection.
Checkpoint blockade has revolutionized cancer therapy, yet durable responses are limited by myeloid-driven immunosuppression. Bexmarilimab, a first-in-class monoclonal antibody targeting the scavenger receptor Clever-1 (Stabilin-1), represents a novel strategy to recondition tumor-associated macrophages and malignant myeloid cells. This review summarizes the biological rationale for Clever-1 targeting, appraises clinical and translational evidence, and outlines strategies to enhance therapeutic efficacy through patient selection, rational drug combinations, biomarker-driven patient stratification, and timing of intervention. We also highlight future opportunities for integrating bexmarilimab with next-generation immunotherapies and precision medicine approaches.
No takes yet. Share an insight, caveat, or question.
Karthikeyan et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: